TIAA CREF Investment Management’s Immunic IMUX Stock Holding History

TIAA CREF Investment Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-117	Closed	-$319K	–	3067
2018 Q2	$319K	Buy	+117	New	+$270K	﹤0.01%	2932
2017 Q2	–	Sell	-194	Closed	-$310K	–	3153
2017 Q1	$310K	Sell	194 -5	-3%	-$9.15K	﹤0.01%	2918
2016 Q4	$346K	Sell	199 -4	-2%	-$8.76K	﹤0.01%	2945
2016 Q3	$497	Hold	203	–	–	﹤0.01%	2845
2016 Q2	$503K	Buy	203 +2	+1%	+$6.57K	﹤0.01%	2852
2016 Q1	$730K	Sell	201 -10	-5%	-$34.7K	﹤0.01%	2632
2015 Q4	$971K	Buy	211 +72	+52%	+$235K	﹤0.01%	2602
2015 Q3	$225K	Buy	139 +38	+38%	+$190K	﹤0.01%	3026
2015 Q2	$848K	Buy	101 +54	+115%	+$515K	﹤0.01%	2775
2015 Q1	$475K	Hold	47	–	–	﹤0.01%	2934
2014 Q4	$474K	Hold	47	–	–	﹤0.01%	2981
2014 Q3	$382K	Hold	47	–	–	﹤0.01%	3026
2014 Q2	$509K	Buy	+47	New	+$330K	﹤0.01%	3003

Other funds holding IMUX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TIAA CREF Investment Management's IMUX Position: Q3 2018 in Review

TIAA CREF Investment Management sold out of Immunic (IMUX) in Q3 2018, closing a stake of 117 shares — an estimated $319K sold.

TIAA CREF Investment Management first reported a position in IMUX in Q2 2014 and held it in 13 quarters. The position peaked at $971K in Q4 2015. 54 funds tracked by Wall St. Rank hold IMUX as of Q3 2018.

TIAA CREF Investment Management reported no remaining Immunic position as of Q3 2018 after selling out during the quarter.
TIAA CREF Investment Management sold 117 Immunic shares in Q3 2018, an estimated $319K.
TIAA CREF Investment Management first reported a position in Immunic in Q2 2014 and held it in 13 quarters.
TIAA CREF Investment Management's Immunic position peaked at $971K in Q4 2015.
54 funds tracked by Wall St. Rank held Immunic as of Q3 2018.

Based on TIAA CREF Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.